1
Total investments
1
Early stage
0
Mid stage
0
Late stage
12y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Oct 2014
PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline.
PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.
Experience · 2 entries
All (2)
Investments (1)
Founder (1)
Board (1)
2014
Co-Founder
Oct 2014
PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline.
PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.
Board Member
Oct 2014
PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline.
PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.